Sparteine sulfate

CAS No. 299-39-8

Sparteine sulfate( —— )

Catalog No. M18386 CAS No. 299-39-8

Sparteine sulfate is a class 1a antiarrhythmic agent and a sodium channel blocker. It can chelate the bivalents calcium and magnesium.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 95 Get Quote
10MG 170 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Sparteine sulfate
  • Note
    Research use only, not for human use.
  • Brief Description
    Sparteine sulfate is a class 1a antiarrhythmic agent and a sodium channel blocker. It can chelate the bivalents calcium and magnesium.
  • Description
    Sparteine sulfate is a class 1a antiarrhythmic agent and a sodium channel blocker. It can chelate the bivalents calcium and magnesium.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    Sodium Channel
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    299-39-8
  • Formula Weight
    332.46
  • Molecular Formula
    C15H28N2O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=S(=O)(O)O.C1CCCN2C[C@@H]3C[C@@H](CN4CCCC[C@@H]34)[C@@H]12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Gawali VS, et al. C2-Modified Sparteine Derivatives Are a New Class of Potentially Long-Acting Sodium Channel Blockers. ChemMedChem. 2017 Nov 22;12(22):1819-1822.
molnova catalog
related products
  • Brivanib alaninate

    A prodrug of Brivanib, which is a dual inhibitor of VEGFR2 and FGFR1 with IC50 of 25 nM and 148 nM respectively.

  • Pazopanib

    A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.

  • UNC0064-12

    2,4-Pyrimidinediamine with linker is a patent compound in WO2013055780A1.